I totally agree!!! After TLD and other PR's, providing the news is supportive, I would think that Northwest would consider a RS to provide a higher SP and facilitate institutional buying. Those are the fun types of maneuvers and strategies when the company is in strong demand.It's analogous to an oil and gas company that has super strong reserves and stable cash flows. Every institution wants a position in that kind of company and the company tries to make it easy for the institutions to park large sums of money . What institutions don't like is a company that insults their intelligence by trying to create the illusion of large reserves by fracking wells into huge flow rates and equating big flow rates with big reserves .All fracking does is flush oil and gas out faster than conventional methods. There not creating any new reserves by fracking, just creating higher flow rates. For Northwest, the product is whatever it is. If it's successful in application , one would assume that that only issue would be one of manufacturing and implementation /distribution. As for maintaining their listing, there's no way that should be a problem if they have a good product. AND my hunch is that a major pharma company would rather spend their dollars to buy Northwest rather than throw away money trying to suppress the SP.Again, if the product is good, Northwest will have the "world by the tail" !!!!AND some major Pharma company will pay whatever it takes to control the world ofr immunotherapy in cancer treatments .Remember, BP is vertically integrated and can afford to pay Northwest 100% of the anticipated future net revenues for the life of the application(s) and still make trillions from their hospital division, their ........... !!! All they care about is owning and controlling the resource, which in this case is DCVax-L and Direct!!! Northwest and other small biotech companies don't have the luxury of being vertically integrated!!!
AI
Market Data 
Markets 
